Harpoon Therapeutics, Inc. (HARP)

NASDAQ: HARP · IEX Real-Time Price · USD
+0.021 (3.08%)
Jun 2, 2023, 11:19 AM EDT - Market open

Company Description

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States.

The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors.

Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors.

Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Harpoon Therapeutics, Inc.
Harpoon Therapeutics logo
Country United States
Founded 2015
IPO Date Feb 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Ms. Julie M. Eastland M.B.A.

Contact Details

131 Oyster Point Boulevard, Suite 300
South San Francisco, California 94080
United States
Phone 650-443-7400
Website harpoontx.com

Stock Details

Ticker Symbol HARP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001708493
CUSIP Number 41358P106
ISIN Number US41358P1066
Employer ID 47-3458693
SIC Code 2836

Key Executives

Name Position
Julie M. Eastland M.B.A. President, Chief Executive Officer and Director
Dr. Natalie R. Sacks M.D. Consultant
Georgia L. Erbez Consultant
Dr. Holger Wesche Ph.D. Chief Scientific Officer
Wendy Chang Senior Vice President of Human Resources
Rachael Lester Senior Vice President of Business Development and Corporate Strategy
Dr. Banmeet Anand Ph.D. Senior Vice President of Translational Medicine
Dr. Luke N. Walker M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 30, 2023 EFFECT Notice of Effectiveness
May 30, 2023 424B3 Prospectus
May 19, 2023 S-3 Registration statement under Securities Act of 1933
May 16, 2023 424B5 Filing
May 15, 2023 EFFECT Notice of Effectiveness
May 12, 2023 8-K Current Report
May 11, 2023 10-Q Quarterly Report
May 11, 2023 S-3/A [Amend] Registration statement under Securities Act of 1933
Apr 27, 2023 ARS Filing
Apr 27, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material